share_log

JMP Securities Reiterates Market Outperform on Blueprint Medicines, Maintains $114 Price Target

Moomoo 24/7 ·  Apr 10 11:02

JMP Securities analyst Reni Benjamin reiterates Blueprint Medicines (NASDAQ:BPMC) with a Market Outperform and maintains $114 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment